CIPRO XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO XR is an extended-release oral tablet formulation of ciprofloxacin, a fluoroquinolone antibiotic indicated for urinary tract infections. The drug works by inhibiting bacterial DNA gyrase, an essential enzyme for bacterial DNA replication and repair. It is a small-molecule antibiotic approved in 2002.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team focus is shifting from growth to market defense and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections
Started Mar 2004
212 enrolled
Urinary Tract Infection
A Phase IV Study of Cipro XR in Uncomplicated UTI
Started Feb 2003
7,614 enrolled
Urinary Tract Infections
Career Relevance
CIPRO XR offers limited growth career trajectory due to LOE approaching and zero linked job openings. Roles on this team focus on managing decline, controlling costs, and executing generic transition strategies rather than driving commercial expansion or clinical innovation. Bayer's focus is likely on defending market position and protecting downstream revenues during LOE.
Worked on CIPRO XR at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.